SequelSEC

Xilio Therapeutics, Inc. XLO

Pharmaceutical Preparations · CIK 0001840233 · Fiscal year ends 1231

Revenue
$43.77M
Fiscal year ended 2025-12-31
Operating income
-$41.98M
Fiscal year ended 2025-12-31
Free cash flow
-$5.51M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$34.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$6.04Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth589.9%93th
Current ratio2.58x35th
FCF margin-12.6%64th
Operating margin-95.9%60th
CapEx / revenue1.2%42th
SBC / revenue15.9%43th
Net margin-80.1%57th
R&D / revenue128.0%46th

Xilio Therapeutics, Inc. (XLO) reported revenue of $43.77M and net income of -$35.04M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Xilio Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Xilio Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$43.77M$6.34M
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating income-$41.98M-$60.58M
Net income-$35.04M-$58.24M
Research & development$56.04M$41.21M
Weighted-average diluted sharesUnavailableUnavailable
Pretax income-$35.04M-$58.24M
Income tax expense$0$0
Diluted EPS$-4.19$-15.24
Selling, general & administrativeUnavailableUnavailable
General & administrative$29.71M$24.78M
Selling & marketingUnavailableUnavailable

Balance

Xilio Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$137.53M$55.29M
Total assets$154.68M$71.08M
Current assets$145.03M$60.23M
Total liabilities$119.41M$53.48M
Current liabilities$56.27M$27.26M
Total equity incl. NCI$35.27M$17.60M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$3.17M$2.57M

Cash flow

Xilio Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$4.99M-$18.38M
Capital expenditures$518.00K$36.00K
Investing cash flow-$518.00K-$36.00K
Financing cash flow$87.78M$29.20M
Net change in cash$82.26M$10.78M
Stock-based compensation$6.94M$6.43M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortization$1.54M$1.64M

Derived

Xilio Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flow-$5.51M-$18.41M
Gross marginUnavailableUnavailable
Operating margin-95.9%-954.9%
FCF margin-12.6%-290.3%
SBC / revenue15.9%101.4%
Current ratio2.58x2.21x
Revenue YoY growth589.9%Unavailable
Net margin-80.1%-918.0%
R&D / revenue128.0%649.6%
CapEx / revenue1.2%0.6%
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open XLO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.